Glycogen storage disease type II - PDFSEARCH.IO - Document Search Engine

Glycogen storage disease type II
Results: 169

#	Item
141	Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease CRANBURY, N.J., March 8, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: Add to Reading List Source URL: www.unitedpompe.com Language: English - Date: 2011-03-08 17:31:25 Medicine Food and Drug Administration Pharmaceutical industry Research Lysosomal storage diseases Glycogen storage disease type II Clinical trial New Drug Application Amyotrophic lateral sclerosis Health Clinical research Rare diseases
142	Amicus Therapeutics Announces Second Quarter 2007 Financial Results Add to Reading List Source URL: www.unitedpompe.com Language: English - Date: 2011-12-11 11:39:13 Clinical research Lysosomal storage diseases Glycogen storage disease type II Hepatology Enzyme replacement therapy Acid alpha-glucosidase Clinical trial ERT Amyotrophic lateral sclerosis Health Medicine Rare diseases
143	Pompe Program Update March 2, 2009 Supply Update In January 2009, Genzyme notified the Pompe community that we were experiencing a temporary constraint in the global supply of Myozyme® (alglucosidase alfa) produced at t Add to Reading List Source URL: www.unitedpompe.com Language: English - Date: 2009-03-02 20:03:34 Hepatology Alglucosidase alfa Genzyme Food and Drug Administration William Canfield Medicine Health Glycogen storage disease type II
144	October 11, 2012 Amicus Therapeutics Announces Positive Pompe Program Updates AT2220-Enzyme Replacement Therapy (ERT) Co-Administration Increases Pompe Enzyme (rhGAA) Activity in First 3 Dose Cohorts in Phase 2 Study AT Add to Reading List Source URL: www.unitedpompe.com Language: English - Date: 2012-11-15 18:10:29 Lysosomal storage diseases Glycogen storage disease type II Hepatology Alglucosidase alfa Enzyme replacement therapy ERT Amyotrophic lateral sclerosis Immunogenicity Medicine Health Rare diseases
145	Expensive drug gives hope to rare disease sufferer Family wonders who will pay bill Trevor Pare, 16, suffers from a rare form of muscular dystrophy. He and his mother, Linda, worry his condition will worsen if the provin Add to Reading List Source URL: www.unitedpompe.com Language: English - Date: 2007-03-14 17:43:04 Pharmacology Glycogen storage disease type II Hepatology Alglucosidase alfa Genzyme Clinical trial Muscular dystrophy Pharmaceutical industry Drug Health Medicine Pharmaceutical sciences
146	MYOZYME® (2000 L) SUPPLY UPDATE – US VERSION – JANUARY 2009 We would like to take this opportunity to provide an important update to the Pompe Community. Background In the early stages of development of Myozyme® (a Add to Reading List Source URL: www.unitedpompe.com Language: English - Date: 2009-01-14 20:25:55 Hepatology Orphan drugs Alglucosidase alfa Genzyme Medicine Health Glycogen storage disease type II
147	Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease CRANBURY, N.J., October 23, [removed]Amicus Therapeutics, a biopharmaceutical company developing small molecule, Add to Reading List Source URL: www.unitedpompe.com Language: English - Date: 2007-10-23 11:26:48 Science Clinical research Design of experiments Glycogen storage disease type II Hepatology Clinical trial Molecular chaperone therapy Health Medicine Lysosomal storage diseases
148	Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease CRANBURY, N.J., June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company Add to Reading List Source URL: www.unitedpompe.com Language: English - Date: 2008-06-03 09:27:22 Lysosomal storage diseases Glycogen storage disease type II Hepatology Motor neurone disease Acid alpha-glucosidase Amyotrophic lateral sclerosis Clinical trial Molecular chaperone therapy Health Rare diseases Medicine
149	March 19, 2012 Community Update for Pompe Families in the United States who Utilize Myozyme® (alglucosidase alfa) Produced at the 160 L Manufacturing Scale We are writing to provide an update to those families who are c Add to Reading List Source URL: www.unitedpompe.com Language: English - Date: 2012-03-19 20:39:14 Clinical research Epidemiology Genzyme Clinical trial Glycogen storage disease type II William Canfield Medicine Health Alglucosidase alfa
150	Pompe Community Update News from Patient Advocacy Summer 2011 Pompe Phase 2 Co-administration Study: AT2220-010 Amicus Therapeutics’ Pompe Program is proceeding with a Phase 2 co-administration study of AT2220, the inv Add to Reading List Source URL: www.unitedpompe.com Language: English - Date: 2011-08-10 11:05:44 Clinical research Lipid storage disorders Lysosomal storage diseases Pharmaceutical industry Glycogen storage disease type II Enzyme replacement therapy Fabry disease Alglucosidase alfa Clinical trial Health Medicine Rare diseases

UPDATE